Stephan Bildat
Herford Hospital · 32 works · 909 citations · h-index 10
Top works
- Phase II Comparator Study of Oral Versus Intravenous Topotecan in Patients With Chemosensitive Small-Cell Lung Cancer
- Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
- Preoperative chemoradiotherapy and surgery for selected non-small cell lung cancer IIIB subgroups: long-term results
- High-risk additional chromosomal abnormalities at low blast counts herald death by CML
- 10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45Gy (1.5Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)—A multicenter phase-II trial (CISTAXOL)
- Lung cancer: Combined modality therapy in NSCLC
- Induction chemotherapy followed by concurrent chemotherapy and definitive high-dose radiotherapy for patients with locally advanced non-small-cell lung cancer (stages IIIa/IIIb):a pilot phase I/II trial
- Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV
- W4255001269
- Quality of life and outcome of patients with metastatic pancreatic cancer receiving first‐line chemotherapy with nab‐paclitaxel and gemcitabine: Real‐life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registry
- Phase I study of docetaxel in combination with gemcitabine as first line chemotherapy (CT) in patients with metastatic non-small cell lung cancer (NSCLC)
- Final Evaluation of Randomized CML-Study IV: 10-Year Survival and Evolution of Terminal Phase
- P-604 Multicenter German/French phase-II trial of induction-CTx followed by concurrent CTx/RTx +/- surgery (S) in locally far advanced inoperable non-small-cell lung cancer (NSCLC) stages IIIA(N2) and IIIB - preliminary results of toxicity and efficacy including a newer induction-CTx regimen
- Preoperative treatment strategies in stage III non-small cell lung cancer
- Correction: High-risk additional chromosomal abnormalities at low blast counts herald death by CML
- “Minimal N2-disease” (operable) stage IIIa non-small cell lung cancer: Prospectively randomized multicenter German phase-III-trial of surgery (S) followed by adjuvant radiotherapy (RTx) versus “Trimodality treatment” — Early results of feasibility and toxicity in this setting
- Long-term survival (S) of induction chemotherapy (CTx) with three cycles cisplatin (cis)/paclitaxel (pac) followed by concurrent (cc) chemoradiation (CTx/RTx) cis/etoposide (eto) and 45 Gy (1.5 Gy bid) plus surgery (SURG): Phase II results (CISTAXOL).
- O-213 Operable stage IIIA NSCLC: prospectively randomized multicenter German trial of surgery and postoperative radiotherapy versus “trimodality treatment” — analysis of surgical results and toxicity
- ASSESSMENT OF IMATINIB 400MG AS FIRST LINE TREATMENT OF CHRONIC MYELOID LEUKEMIA: 10-YEAR SURVIVAL RESULTS OF THE RANDOMIZED CML STUDY IV
- SS-2 Combined modality therapy in unresectable stage III NSCLC